1. |
Peripheral opioid agonists for pain management? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1404,
2003,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
2. |
A consensus statement on the use of IV immunoglobulins in patients with autoimmune mucocutaneous blister diseases has been issued |
|
Inpharma Weekly,
Volume &NA;,
Issue 1404,
2003,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
3. |
HAART accounts for large increase in HIV/AIDS costs in Canada |
|
Inpharma Weekly,
Volume &NA;,
Issue 1404,
2003,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
4. |
Enfuvirtide: cost and QOL effect in HIV infections |
|
Inpharma Weekly,
Volume &NA;,
Issue 1404,
2003,
Page 5-6
K Salmon,
Preview
|
|
摘要:
Enfuvirtide [T 20, 'Fuzeon'] is the first drug in a new class of antiretroviral agents known as HIV-1 fusion inhibitors. The addition of enfuvirtide to an optimised background regimen in treatment-experienced patients with HIV-1 infections has been found in two large pivotal phase III trials to significantly decrease plasma viral load and significantly increase CD4+ cell count at 24 weeks. However, enfuvirtide is a costly drug and works best in conjunction with other active drugs, thus its cost effectiveness is a salient issue in the HIV infections treatment arena. In addition, as enfuvirtide requires twice-daily injections, and often causes painful injection-site reactions which persist throughout therapy, its impact on patients' health-related QOL (HRQOL) is of great interest to physicians and patients alike. These issues were examined in studies which were presented at poster sessions during the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment [Paris, France; July 2003].
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
5. |
Reduced vibration detection predicts higher diabetic complication costs |
|
Inpharma Weekly,
Volume &NA;,
Issue 1404,
2003,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
6. |
Diagnostic agent (18F-FDG): therapeutic potential in breast cancer? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1404,
2003,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
7. |
R&D News from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment |
|
Inpharma Weekly,
Volume &NA;,
Issue 1404,
2003,
Page 8-10
RM Poole,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
8. |
3,4-diaminopyridine: promising therapy for downbeat nystagmus? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1404,
2003,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
9. |
Pemetrexed + cisplatin: first-line for malignant pleural mesothelioma |
|
Inpharma Weekly,
Volume &NA;,
Issue 1404,
2003,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
10. |
Have a gutful with a peptide |
|
Inpharma Weekly,
Volume &NA;,
Issue 1404,
2003,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|